BEOVU Versus Eylea in the Treatment of Age-related Macular Neovascular Degeneration

Last updated: May 11, 2021
Sponsor: Benha University
Overall Status: Active - Recruiting

Phase

N/A

Condition

Geographic Atrophy

Macular Degeneration

Treatment

N/A

Clinical Study ID

NCT04882956
Hamaky11
  • Ages > 18
  • All Genders

Study Summary

Age-Related macular neovascularization degeneration occur is a vision threatening condition. The investigators compare the efficacy of BEOVU and Eylea intravitreal treatment in the management.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • • Age-Related macular neovascularization degeneration

Exclusion

Exclusion Criteria:

  • other causes of macular neovascularization degeneration
  • other macular diseases

Study Design

Total Participants: 40
Study Start date:
August 05, 2020
Estimated Completion Date:
March 31, 2022

Study Description

Baseline ,and postoperative 1 ,6 and 12 months full ophthalmic examination was done. Procedure included randomized intravitreal injection of Brolucizumab (BEOVU®, Genentech, South Francisco, CA) and of aflibercept (Eylea; Regeneron, Tarrytown,NY)

Connect with a study center

  • INMC

    Abu Dhabi, 46266
    United Arab Emirates

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.